Innate Pharma (IPHA) Cash from Discontinued Operations (2020 - 2025)
Innate Pharma's (IPHA) quarterly Cash from Discontinued Operations came in at 61409115.62 in Q4 2025, down 733.34% YoY from 9696072.28 in Q4 2024, and down 733.34% on a QoQ basis from 7369033.88 in Q4 2024.
Innate Pharma (IPHA) Cash from Discontinued Operations (2020 - 2025) Analysis & Trends
Innate Pharma (IPHA) has 6 years of Cash from Discontinued Operations data on file, last reported at 61409115.62 in Q4 2025.
- Quarterly Cash from Discontinued Operations fell 733.34% year-over-year to 61409115.62 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 116294195.15 (down 56.25% YoY) and the FY2025 annual result came in at 61409115.62, down 733.34% from the prior year.
- Cash from Discontinued Operations slipped to 61409115.62 in Q4 2025, from 7369033.88 in the prior quarter.
- In the past five years, Cash from Discontinued Operations ranged from a high of 7369033.88 in Q4 2024 to a low of 66873109.89 in Q4 2021.
- A 5-year average of 34319664.26 and a median of 35031527.5 in 2023 frame the typical range for Cash from Discontinued Operations.
- Annual changes were most pronounced in 2024 — Cash from Discontinued Operations jumped 78.96% — and 2025, when it slumped 733.34%.
- Tracing IPHA's Cash from Discontinued Operations over 5 years: stood at 66873109.89 in 2021, then soared by 70.78% to 19542838.28 in 2022, then slumped by 79.26% to 35031527.5 in 2023, then surged by 78.96% to 7369033.88 in 2024, then plunged by 733.34% to 61409115.62 in 2025.
- The last three Cash from Discontinued Operations figures came in at 61409115.62 (Q4 2025), 7369033.88 (Q4 2024), and 35031527.5 (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Discontinued Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Innate Pharma | 202.03 Mn | 202.03 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -61.41 Mn |
| Dec 31, 2025 | -61.41 Mn |
| Dec 31, 2024 | -7.37 Mn |
| Dec 31, 2024 | -7.37 Mn |
| Dec 31, 2023 | -35.03 Mn |
| Dec 31, 2023 | -35.03 Mn |
| Jun 30, 2023 | -12.48 Mn |
| Jun 30, 2023 | -12.48 Mn |
| Dec 31, 2022 | -19.54 Mn |
| Dec 31, 2022 | -19.54 Mn |
| Dec 31, 2021 | -66.87 Mn |
| Dec 31, 2021 | -66.87 Mn |
| Jun 30, 2021 | -37.53 Mn |
| Jun 30, 2021 | -37.53 Mn |
| Dec 31, 2020 | -61.72 Mn |
| Dec 31, 2020 | -61.72 Mn |
| Jun 30, 2020 | -63.91 Mn |
| Jun 30, 2020 | -63.91 Mn |